COMPANY PROFILE

Pinteon Therapeutics

Explore full profile

Pinteon Therapeutics focuses on the discovery and development of breakthrough therapeutics targeting Pin1

Newton, United StatesFounded 2014Biotech & Life Sciences

Valuation $100–250M Last recorded · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Pinteon Therapeutics

Pinteon Therapeutics is a biotechnology company focused on developing innovative therapies to maintain brain health in patients with neurodegenerative diseases by interrupting the spread of toxic tau proteins. The company primarily serves patients suffering from conditions such as Alzheimer's disease and other tauopathies. Operating in the biopharmaceutical market, Pinteon employs a research-driven business model, leveraging cutting-edge scientific discoveries to create therapeutic solutions. The company generates revenue through the development and potential commercialization of its proprietary treatments, as well as through partnerships and collaborations with other pharmaceutical entities. Pinteon's core product, PNT001, is designed to target and neutralize toxic tau, thereby preventing the progression of neurodegenerative diseases. The company is led by a team of experienced scientists and industry professionals, including CEO Martin Jefson, Ph.D., and Chief Scientific Officer Henrik Zetterberg, M.D., Ph.D.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Newton, United States
Employees: 3
Open positions: None listed
Dealroom signal: 57.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Neurology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Jan 2022	$25M	$100M	Undisclosed	↗
SERIES A✓Equity / VC	Oct 2019	$17M	$68M	5Y Capital	—

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Pinteon Therapeutics website traffic

Latest recorded traffic for Pinteon Therapeutics is 810 monthly website visits, up 189.3% over the last three months. Pinteon Therapeutics's team grew 0% over the past year.

Latest monthly visits810 3-month web change+189.3% 1-year team growth0%

Monthly website visitsOct 2017–Oct 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAmbagon TherapeuticsBiotechnology company developing small molecule drugs that target previously undruggable proteins for cancer treatment	Eindhoven, Netherlands	Operational	15	$97M	$425M
DXDxCoverDeveloping a spectroscopic liquid biopsy for rapid detection of cancer	Glasgow, United Kingdom	Operational
BIBioMindBioMind is developed in collaboration with the world's largest hospital for neurological diseases	Singapore, Singapore	Operational
MTMedicenna TherapeuticsClinical stage, privately held, immuno-oncology company	Vancouver, Canada	Operational
CTCARsgen TherapeuticsA leading immunotherapy company focused on the development of new chimeric antigen receptor	Xuhui District, China	Operational
STSapience TherapeuticsA preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs	Town of Greenburgh, United States	Operational
THTheraBiologicsA proprietary human nsc platform for cancer treatment	United States	Operational
BIBioImageneTissue-based integrated hardware and software solutions for clinical diagnostics and drug discovery applications	Sunnyvale, United States	Acquired